Long-term propylthiouracil use and acute myeloid leukemia: a case report and review of the literature.
Focosi
Daniele
D
Caracciolo
Francesco
F
Galimberti
Sara
S
Papineschi
Federico
F
Petrini
Mario
M
D000328:Adult; D000963:Antimetabolites / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D002889:Chromosomes, Human, Pair 2 / Q000235:genetics; D002891:Chromosomes, Human, Pair 21 / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007453:Iodide Peroxidase / Q000037:antagonists & inhibitors*; D015470:Leukemia, Myeloid, Acute / Q000201:enzymology* / Q000235:genetics / Q000628:therapy*; D009195:Peroxidase / Q000037:antagonists & inhibitors*; D011441:Propylthiouracil / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D013997:Time Factors; D014178:Translocation, Genetic; D014184:Transplantation, Homologous
D000963:Antimetabolites; D003561:Cytarabine; D005047:Etoposide; D011441:Propylthiouracil; D009195:Peroxidase; D007453:Iodide Peroxidase; D015255:Idarubicin